HHS Secretary Highlights Hormone Replacement Therapy for Menopausal Women

Secretary of Health and Human Services, Robert F. Kennedy Jr., has pointed out the positive aspects of hormone replacement therapy (HRT) for women going through menopause.

“We are starting to lift extensive black box warnings from menopausal hormone replacement therapy products,” he shared on Monday.

HRT is available in various forms, including tablets, patches, injections, sprays, and creams, all of which currently carry the black box label—the FDA’s most severe safety warning.

Due to these warning labels, “women might be underusing approved treatments that could ease menopausal symptoms and enhance their health,” the HHS advised in a recent press statement.

For over two decades, America’s healthcare system has overlooked women. Many have been made to fear the very treatment that could empower them during one of life’s toughest transitions: menopause.

That changes today.

Menopause is the stage when a woman stops menstruating and can no longer conceive, typically occurring around age 52 in the U.S., according to the National Institute on Aging.

As women age, the number of functioning follicles in their ovaries decreases; these follicles release hormones like estrogen and progesterone, which are vital for various bodily functions. So, this reduction might explain menopausal symptoms such as weight gain, hot flashes, sleep issues, and mood swings.

This portrayal has sometimes led to the stereotype of the irritable menopausal woman. If HRT can ease these struggles, perhaps it deserves more applause than skepticism.

Kennedy seems to be advocating for that perspective.

Today marks important progress in women’s health, including the FDA’s decision to start removing HRT black box warnings, the first approval of a generic Premarin in over 30 years, and a new non-hormonal treatment for menopause. More choices mean better access and informed decisions.

“We are advocating for every woman experiencing menopausal symptoms, ensuring she knows her options and can pursue life-changing treatments,” Kennedy stated, according to the Department of Health. “Bad science and bureaucratic delays have given women and doctors an incomplete understanding of medicine regarding hormone replacement therapy. We’re returning to evidence-based practices and empowering women in their health choices.”

Kennedy referred to a 2002 study by the Women’s Health Initiative, which noted a statistically non-significant rise in breast cancer risk among participants, who were on average 63 years old and had been postmenopausal for approximately a decade.

The study examined women taking estrogen and progestin, the latter being a synthetic version of progesterone.

Clinical studies also suggested that while FDA Commissioner Marty McCulley noted that data doesn’t support a link between HRT and increased breast cancer risk, he acknowledged that many still hold onto those concerns.

In Parkinson’s research, ratios of hormone levels show that despite HRT users having higher estrogen levels, progesterone levels remained comparable to those who did not undergo HRT.

Estrogen dominance can be linked with certain cancers, including breast cancer, and symptoms of this condition often overlap with those of menopause, such as irregular periods and mood swings. It’s essential to recognize the role of both estrogen and progesterone in women’s health.